Mitsubishi UFJ Trust & Banking’s TG Therapeutics TGTX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Buy	+8,580	New	+$351K	﹤0.01%	1079

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's TGTX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in TG Therapeutics (TGTX) in Q2 2026: 8,580 shares worth $471K. The stake represents ﹤0.01% of the portfolio and ranks #1079 among its holdings.

427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 8,580 shares of TG Therapeutics worth $471K as of Q2 2026.
TG Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1079 holding.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.